Expanded Access Program for Cancer Treatment with Balstilimab and Zalifrelimab

Program Overview

This program allows patients who have previously been treated with balstilimab, either alone or with zalifrelimab, in a clinical trial to continue their treatment. It is designed for patients who have experienced positive results and want to keep receiving these medications. The program can accommodate up to 100 participants, and each patient's treatment will be reviewed every year to ensure they are still benefiting from the medication.

Description

The expanded access program is designed for patients who have already participated in a clinical trial involving balstilimab and/or zalifrelimab and have seen positive effects from the treatment. This program allows these patients to continue receiving the medication, either as a single treatment or in combination, depending on what they received in the trial. The program will include up to 100 participants, and each year, doctors will check to see if the treatment is still working well for each patient. This ensures that patients continue to receive the best possible care.

Eligibility Criteria